272 related articles for article (PubMed ID: 35429731)
1. Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC.
Zheng S; Li L; Chen M; Yang B; Chen J; Liu G; Shao Z; Wu J
Breast; 2022 Jun; 63():177-186. PubMed ID: 35429731
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors and Survival Outcomes of Patients With Early HER2+ Breast Cancer Treated With Trastuzumab in a Brazilian Public Reference Center: A Real-World Study.
Mattar A; Hegg R; Tayar DO; Rocha M; Terzian ALB; Oliveira RW; Julian GS; Gebrim LH
Clin Breast Cancer; 2023 Dec; 23(8):864-875.e7. PubMed ID: 37802752
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
[TBL] [Abstract][Full Text] [Related]
5. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
[TBL] [Abstract][Full Text] [Related]
8. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
[TBL] [Abstract][Full Text] [Related]
9. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
10. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Palmieri C; Macpherson IR; Yan K; Ades F; Riddle P; Ahmed R; Owadally W; Stanley B; Shah D; Gojis O; Januszewski A; Lewanski C; Asher R; Lythgoe D; de Azambuja E; Beresford M; Howell SJ
Oncotarget; 2016 Mar; 7(11):13209-20. PubMed ID: 26334099
[TBL] [Abstract][Full Text] [Related]
12. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
[TBL] [Abstract][Full Text] [Related]
13. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
Qiao W; Guo W; Liu Q; Guo X; Deng M
Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis.
Xia LY; Cao XC; Yu Y
World J Surg Oncol; 2024 Apr; 22(1):106. PubMed ID: 38643188
[TBL] [Abstract][Full Text] [Related]
15. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
[TBL] [Abstract][Full Text] [Related]
16. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
17. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
18. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
[TBL] [Abstract][Full Text] [Related]
19. EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
Leichsenring J; Vladimirova V; Solbach C; Karn T; Ataseven B; Sinn BV; Barinoff J; Müller V; Blohmer JU; Schem C; Engels K; Marmé F; Fisseler-Eckhoff A; Fasching PA; Stickeler E; van Mackelenbergh M; Denkert C; Stenzinger A; Loibl S; Gröschel S
BMC Cancer; 2022 Oct; 22(1):1040. PubMed ID: 36195836
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
